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ABSTRACT
Acute and chronic graft-versus-host disease (GVHD) continue to be major limitations to successful hemato-
poietic stem cell transplantation. A variety of different immunosuppressive and immunomodulating modalities
have been tested in chronic GVHD, among them extracorporeal photopheresis. Photopheresis is currently
indicated and Food and Drug Administration–approved for the treatment of skin manifestations of cutaneous
T-cell lymphoma, where the response rate has proved to be considerably high. Extracorporeal photochemo-
therapy has been evaluated in small cohorts of patients with both acute and chronic GVHD. In steroid-
refractory acute GVHD of the skin and liver, the reported response rate is more than 60%, especially in
patients with less severe forms of the disease. There is more extensive experience in the treatment of chronic
GVHD; overall response rates of 50% and higher have been reported in patients with skin, oral, eye, liver,
gastrointestinal, or lung involvement. At our center, we analyzed 63 patients who had 3 or fewer lines of
immunosuppressant, including tacrolimus and steroids, to avoid the confounding effects of numerous immu-
nosuppressive therapies. The overall response rate was 59% (n  37), and complete responses were seen in 13
patients. The best responses were observed in GVHD of the skin, liver, oral mucosa, and eye. Our results in
chronic GVHD support previous reports of objective responses of skin and visceral GVHD to extracorporeal
photopheresis. All of these results indicate activity of extracorporeal photopheresis in acute and chronic
GVHD, which warrants further evaluation of this therapy in well-designed, prospective, controlled studies.
© 2006 American Society for Blood and Marrow Transplantation
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TNTRODUCTION
Despite adequate posttransplantation immunosuppres-
ive therapy, acute graft-versus-host disease (GVHD)
emains a major cause of morbidity and mortality in
he hematopoietic stem cell transplantation (SCT)
etting, even in patients who receive HLA antigen–
dentical sibling grafts. Up to 30% of the recipients of
tem cells or bone marrow transplantation from HLA
ntigen–identical related donors and most patients who
eceive cells from other sources (matched, unrelated,
on-HLA antigen–identical siblings; cord blood) will
evelop grade 2 acute GVHD despite immunosup-
ressive prophylaxis [1-4]. Most of these patients will
o on to develop chronic GVHD, the other major
imitation of successful allogeneic hematopoietic SCT o
B & M T4,5]. Chronic GVHD is a disease of deregulated im-
unity with protean manifestations similar in many
ays to autoimmune diseases. The relative uncom-
onness of the disease, the lack of consensus on what
epresents true manifestations of chronic GVHD, the
ery limited understanding of its pathophysiology, and
he clinical complexity of these patients are all factors
hat have hindered a systematic approach to this prob-
em.
The impact of chronic GVHD is not only in
orbidity and quality of life, but in nonrelapse mor-
ality as well [5,6]. Corticosteroids are considered the
tandard of care for initial treatment of chronic GVHD,
ut only a minority of patients durably responds.
hese patients are subject to long-term complications
f corticosteroid treatment and management of ste-
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3oid-resistant chronic GVHD is not well deﬁned [7].
variety of different immunosuppressive and immu-
omodulating modalities have been tested in chronic
VHD, among them extracorporeal photopheresis
ECP). Photopheresis is currently indicated and Food
nd Drug Administration–approved for the treatment
f skin manifestations of cutaneous T-cell lymphoma,
here the response rate has proved to be considerably
igh [8-10].
Extracorporeal photochemotherapy has been eval-
ated in small cohorts of patients with both acute and
hronic GVHD. Responses were observed in skin,
iver, gastrointestinal (GI) tract, mouth, eye, and lung
11-17]. Unfortunately, the literature is difﬁcult to
nterpret because of the heterogeneity of treatment
chedules and diagnostic and response assessment cri-
eria. In this analysis, we review the potential role of
CP in the management of GVHD and summarize
ur experience with ECP in the management of
hronic GVHD.
CP IN GVHD
cute GVHD
The experience with ECP in the treatment of acute
VHD is less than that with chronic forms of the dis-
ase. Published literature consists of small series of pa-
ients who usually failed previous corticosteroid therapy.
reinix et al. [17] treated 21 patients with steroid-
efractory grades II to IV acute GVHD. Three months
fter initiation of ECP, 60% of patients achieved a com-
lete resolution of GVHD manifestations. Complete
esponse (CR) was obtained in 100% of patients with
rade II, 67% of patients with grade III, and 12% of
atients with grade IV acute GVHD. Three months
fter start of ECP, CR was achieved in 60% of patients
ith cutaneous, 67% with liver, and none with gut
nvolvement. The procedure was well tolerated and ad-
erse events observed during ECP included a decrease in
eripheral blood cell counts in the early post trans-
lantation phase. Survival was 57% at a median
ollow-up time of 25 months after SCT. The authors
oncluded that ECP is an effective adjunct therapy for
cute steroid-refractory GVHD with cutaneous and
iver involvement. Messina et al. [18] reported the
esults of ECP on 33 children with acute GVHD
esistant to conventional immunosuppression. Re-
ponses were high in all organs, including skin
76%), liver (60%), and GI tract (75%). The 5-year
verall survival was 69% for responding patients ver-
us 12% for nonresponders (P  .001).
In these and other publications of smaller cohorts
f patients there were differences in the deﬁnition of
teroid-refractoriness, concomitant immunosuppres-
ion, and ECP schedules, and, furthermore, none of
he studies was controlled. Despite these difﬁculties, t
8here is growing evidence of activity, and a random-
zed, phase III study comparing steroids versus ste-
oids plus ECP as ﬁrst-line therapy for acute GVHD
s under way.
hronic GVHD
Most of the experience with ECP in transplanta-
ion is in the management of chronic GVHD. The
ituation here is even more complex because of the
ack of consensus in deﬁnition of chronic GVHD,
taging, and criteria for response to therapy. Most
tudies were designed on the basis of a chronologic
eﬁnition of chronic GVHD (i.e. GVHD occurring
fter day-100 posttransplantation) rather than using a
ore descriptive, clinical approach to the disease. We
now that this deﬁnition misclassiﬁes a substantial
umber of patients who have clinical and prognostic
eatures of acute GVHD as having chronic GVHD
7]. Finally, just as in the case of acute GVHD, there
s marked heterogeneity in schedule and duration of
reatment throughout the literature.
Several retrospective and prospective studies have
hown activity of ECP in the management of chronic
VHD. Greinix et al. [11] treated 15 patients with
xtensive chronic GVHD failing corticosteroids and
aw responses up to 80% in skin, 70% in liver, and all
f the patients with involvement of the oral mucosa.
ases with skin GVHD included sclerodermatous
orms with improvement in contractures. Responses
n ulcerative chronic GVHD of the oral mucosa
howed resolution in 100% of patients. The proce-
ure was well tolerated, and no major toxicities were
eported in this study. Apisarnthanarax et al. [15] re-
orted on 32 heavily pretreated patients with chronic
VHD of the skin, with responses in both lichenoid
nd sclerodermal forms in about half of the patients
CR 22%, partial response 34%). The procedure was
lso well tolerated in this group of patients. There are
everal other reports on the efﬁcacy of ECP for the
reatment of chronic GVHD in small groups of pa-
ients, with overall response rates of 50% and higher
n skin, oral, eye, liver, GI, and lung GVHD [12,13,16].
similar response rate and tolerability was observed
n children with skin and visceral GVHD [14,19]. All
f these reports included patients who had received at
east one line of therapy, in most cases steroids, before
nitiation of ECP.
UR EXPERIENCE
We analyzed all patients treated with ECP (n 
1) between January 1998 and October 2002. We
ocused our analysis on the 63 patients with steroid-
esistant, chronic GVHD who had 3 or fewer lines of
mmunosuppressant including tacrolimus and steroids
o avoid the confounding effects of numerous immu-
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ECP in GVHD
Bosuppressive therapies. Patients’ characteristics are
ummarized on Table 1. Chronic GVHD was deﬁned
ccording to clinical manifestations [7], and all re-
ponses to therapy were analyzed by the same two
bservers. The majority of patients had relapsing
hronic GVHD (n  30, 48%), followed by de novo
n  17, 27%) and progressive (n  16, 25%) forms.
ll patients had received corticosteroids at some point
uring their treatment, and 51 patients (81%) were
till taking them at the time of initiation of ECP.
atients were started on 2 to 3 weekly ECP treatments
nd were tapered by one weekly ECP treatment ac-
ording to clinical response and at the discretion of
he managing physician. Tacrolimus and cyclosporine
ere continued through ECP therapy, as steroids
ere tapered as tolerated. The overall response rate
as 59% (n  37), and CR was seen in 13 patients.
he best responses were observed in GVHD of the
kin (n  28, 56%), liver (n  12, 67%), oral mucosa
n  5, 71%), and eye (n  4, 67%). A total of 28
atients (56%) with skin GVHD responded to ECP
able 1. Patients’ Characteristics
n %
ge, y
<50 48 76
>50 15 24
ex
Female 30 48
Male 33 52
onor type
Matched sibling 38 60
Other 21 33
iagnosis
ALL 2 3
AML/MDS 23 37
CML/MPD 21 33
Lymphoma 13 21
Aplastic anemia 2 3
Sickle cell anemia 1 2
Breast cancer 1 2
VHD prophylaxis
Tacrolimus/MTX 51 81
Tacrolimus/steroids 5 8
Cyclosporine/MTX 1 2
cute GVHD
Grade 2-4 34 54
Grade 0-1 24 38
Unknown 5 8
teroids at ECP
No 11 17
Yes 52 82
o. of prior treatments*
2 40 63
3 23 37
LL indicates acute lymphoblastic leukemia; AML/MDS, acute
myelogenous leukemia/myelodysplastic syndrome; CML/MPD,
chronic myelogenous leukemia/myeloproliferative disorders; ECP,
extracorporeal photopheresis; GVHD, graft-versus-host disease;
MTX, methotrexate.
Including tacrolimus or cyclosporine.herapy, and about half of these responses were seen in F
B & M Tatients with sclerodermal forms (n  14, 50%). In-
eed, the majority of patients with scleroderma (n 
4 of 21, 67%) had objective responses to ECP. Re-
ponses were also seen in liver (n  12, 67%), oral
ucosa (n  5, 71%), eye (n  4, 67%), and bonchi-
litis obliterans (n 6, 54%). There were two cases of
olonic GVHD that responded to ECP, and one pa-
ient with upper GI GVHD showed no response. A
latelet count of less than 100,000/mm3 was associ-
ted with a lower response rate (hazard ratio  0.3,
5% conﬁdence interval 0.1-0.95, P .04). There was
trend toward a higher response rate for patients with
actate dehydrogenase levels less than 1000 IU/L, and
n patients with de novo chronic GVHD when com-
ared with progressive and relapsing forms (hazard
atio 2.8, 95% conﬁdence interval 0.8-10.1, P .1).
he overall survival since initiation of therapy was
1% at 5 years, and the nonrelapse mortality was
3%. The primary cause of death was GVHD (n 
4, 68%), followed by relapse (n  9, 26%), infection
utside the setting of GVHD or its treatment (n  1,
%), and hemorrhage (n  1, 3%). Response to ECP
P  .0001) and thrombocytopenia (100,000 plate-
ets/mm3) (P.0001) were the strongest predictors of
onrelapse mortality in univariate analysis (Figures 1
nd 2). The small number of patients in this study
recluded multivariate analysis.
ONCLUSIONS
ECP has objective activity in the treatment of
cute and chronic GVHD, including in cases of liver
nd lung GVHD where more objective, measurable
esponse parameters are available. The procedure is
verall well tolerated, so far with no fatal toxicities
eported in the literature. Our results in chronic GVHD
upport previous reports of objective responses of skin
nd visceral GVHD to ECP.
All of these results seem to indicate activity ofigure 1. Platelet count and cumulative survival.
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4CP in acute and chronic GVHD, which warrants
urther evaluation of this therapeutic modality in well-
esigned, prospective, controlled studies.
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